(NaturalNews) AstraZeneca has come out making bold claims about their new experimental ovarian cancer drug called olaparib. In clinical trials, the drug company shows that their new drug enables an 83 percent reduction in the risk of ovarian cancer progression.
According to a review by officials from the US Food and Drug Administration, this 83 percent statistic most likely couldn’t be reproduced.
“AstraZeneca has put up some pretty lofty expectations,” said Damien Conover, an analyst at Morningstar. Continue reading